30.75
+0.65%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NeoCore Technology Co
Its shares trade on Taipei Exchange under the ticker 4131.TWO. It has been listed since 12 March 2003. In the fiscal year to 31 December 2024, it reported revenue of TWD 61.5m and a net loss of TWD 48.1m. At that date it held total assets of TWD 340.8m and shareholders' equity of TWD 305.1m.
DR. Chip Biotechnology, Inc. engages in the research, development, manufacture, and sale of biochips. The company is headquartered in Tainan, Tainan. The company went IPO on 2003-03-12. The products include deoxyribonucleic acid / ribonucleic acid (DNA/RNA) sample preparation kits, polymerase chain reaction kits, rapid hybridization equipment, biochips, testing reagents, biological preparations, nucleic acid sequencing detection, biotechnology control hardware and software and related components, biomedical materials, and nutritional supplements. The products are mainly sold domestically and exported to Asia and Europe.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Mar 2003
- Website
- bio-drchip.com.tw ↗
Leadership
Pay as last reported
- Dingmao ZhouChairman of the Board, Chief R&D Officer, since 2022
- Wensheng JiGeneral Manager, Corporate Governance Officer
- Weizhe LuHead of Finance & Accounting
- Guoming HongDirector
- Qianhui LaiDirector
- Taiji ZhouDirector
- Tailong ZhouDirector
- Yongchong ZhuoDirector
- Xueling CaiIndependent Director
- Mr. Tiao-Hsiang ChengIndependent Director
- Yiming ZhouIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NeoCore Technology Co Ltd develops DNA/RNA sample preparation kits for domestic and Asian markets.
- The company manufactures polymerase chain reaction kits and rapid hybridization equipment for biotechnology applications.
- NeoCore Technology Co Ltd offers nucleic acid sequencing detection and biomedical materials for healthcare segments.
Weaknesses
- NeoCore Technology Co Ltd exports products to Asia and Europe but lacks a strong presence in North America.
- The company's products are mainly sold domestically with limited international market penetration.
- NeoCore Technology Co Ltd does not have a significant export presence in North America or South America.
Opportunities
- NeoCore Technology Co Ltd can expand its biotechnology control hardware and software sales in Europe.
- The company can increase its export of biochips to Asian markets through strategic partnerships.
- NeoCore Technology Co Ltd can leverage its DNA/RNA sample preparation kits for new healthcare applications.
Threats
- NeoCore Technology Co Ltd faces competition from established biotechnology firms in Europe.
- The company's reliance on domestic sales poses a risk if Asian markets decline.
- NeoCore Technology Co Ltd must navigate regulatory changes in the European healthcare sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.